J&J sales up; profits down on charges

Johnson & Johnson reported a 19 percent decline in fourth-quarter earnings largely because of restructuring charges, but posted a 9 percent sales gain that reversed a slump in previous quarters. Report

Suggested Articles

tecentriq
Pharma

Roche's Tecentriq scores first-in-class liver cancer nod

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

by Carly Helfand
abbvie
Pharma

AbbVie scores 'game-changer' nod for Oriahnn in uterine fibroids

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

by Carly Helfand
Pharma

Sanofi loses vaccines chief Loew to Ipsen amid C-suite shakeup

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.

by Angus Liu